Validation of In Vitro and In Vivo Methods for Assessing Endocrine Disrupting Chemicals
Open Access
- 1 May 2000
- journal article
- review article
- Published by SAGE Publications in Toxicologic Pathology
- Vol. 28 (3), 432-437
- https://doi.org/10.1177/019262330002800312
Abstract
The concepts that require validation in terms of the subject of endocrine disruption are listed and discussed. The main mechanisms by which endocrine disruption can occur are identified, and the assays required for the detection of adverse endocrine disruption toxicities associated with these mechanisms are discussed. The process of assay validation is considered. The validation of structure-activity relationships, the need for reference chemicals, and the problems recently encountered when attempting to reproduce endocrine disruption data are also explored. The most important conclusions derived from this analysis are that given the immature state of research into endocrine disruption toxicity, testing strategies and the types of assay employed should be kept under constant review; inevitably researchers need to accept the fact that future revision of each assay will be required. Second, given the current absence of any chemical that is universally accepted to be devoid of endocrine toxicity, assay specificity will be difficult to assess, and that imposes the need for alternative objective criteria for assessing the value of individual assays.Keywords
This publication has 31 references indexed in Scilit:
- Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinomaCarcinogenesis: Integrative Cancer Research, 1997
- Hydroxylated Polychlorinated Biphenyls (PCBs) as Estrogens and Antiestrogens: Structure–Activity RelationshipsToxicology and Applied Pharmacology, 1997
- Vinclozolin andp,p′-DDE Alter Androgen-Dependent Gene Expression:In VivoConfirmation of an Androgen Receptor-Mediated MechanismToxicology and Applied Pharmacology, 1997
- Relative binding affinity-serum modified access (RBA-SMA) assay predicts the relative in vivo bioactivity of the xenoestrogens bisphenol A and octylphenol.Environmental Health Perspectives, 1997
- Identification of an Estrogen Response Element Activated by Metabolites of 17β-Estradiol and RaloxifeneScience, 1996
- IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogensMutation Research, 1996
- Neonatal Polychlorinated Biphenyl Treatment Increases Adult Testis Size and Sperm Production in the RatToxicology and Applied Pharmacology, 1996
- Persistent DDT metabolite p,p'–DDE is a potent androgen receptor antagonistNature, 1995
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994
- Functional toxicology: a new approach to detect biologically active xenobiotics.Environmental Health Perspectives, 1993